US Patent

US8828440 — Corticosteroids for the treatment of joint pain

Formulation · Assigned to Flexion Therapeutics Inc · Expires 2031-08-04 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects corticosteroid microparticle formulations for treating joint pain caused by inflammatory diseases like osteoarthritis or rheumatoid arthritis.

USPTO Abstract

Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.

Drugs covered by this patent

Patent Metadata

Patent number
US8828440
Jurisdiction
US
Classification
Formulation
Expires
2031-08-04
Drug substance claim
No
Drug product claim
Yes
Assignee
Flexion Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.